株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

鬱病:パイプライン製品の分析

Depression - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213106
出版日 ページ情報 英文 494 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
鬱病:パイプライン製品の分析 Depression - Pipeline Review, H2 2016
出版日: 2016年09月21日 ページ情報: 英文 494 Pages
概要

鬱病は気分障害で、持続的な悲しみや興味に対する喪失感を引き起こします。大鬱病、大鬱病性障害、または臨床的鬱病として知られています。睡眠障害(不眠症、過眠症)、食欲の変化、不安神経症、興奮または落ち着きのなさ、肉体的問題(背部痛、頭痛)といった兆候や症状が見られます。治療には、抗鬱薬、気分安定剤または抗精神病薬などが含まれます。

当レポートでは、鬱病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

鬱病の概要

治療薬の開発

鬱病:企業で開発中の治療薬

鬱病:大学/機関で研究中の治療薬

鬱病:パイプライン製品の概況

鬱病:企業で開発中の製品

鬱病:大学/機関で研究中の製品

鬱病の治療薬開発に従事している企業

鬱病:治療薬の評価

薬剤プロファイル

鬱病:最近のパイプライン動向

鬱病:休止中のプロジェクト

鬱病:開発が中止された製品

鬱病:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8468IDB

Summary

Global Markets Direct's, 'Depression - Pipeline Review, H2 2016', provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Depression
  • The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
  • The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Depression

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Depression
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Depression Overview
  • Therapeutics Development
  • Depression - Therapeutics under Development by Companies
  • Depression - Therapeutics under Investigation by Universities/Institutes
  • Depression - Pipeline Products Glance
  • Depression - Products under Development by Companies
  • Depression - Products under Investigation by Universities/Institutes
  • Depression - Companies Involved in Therapeutics Development
  • Depression - Therapeutics Assessment
  • Drug Profiles
  • Depression - Dormant Projects
  • Depression - Discontinued Products
  • Depression - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Depression, H2 2016
  • Number of Products under Development for Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Depression - Pipeline by AB Science SA, H2 2016
  • Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Depression - Pipeline by Adamed Sp. z o.o., H2 2016
  • Depression - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Depression - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Depression - Pipeline by Alkermes Plc, H2 2016
  • Depression - Pipeline by Allergan Plc, H2 2016
  • Depression - Pipeline by Alvogen Korea Co., Ltd., H2 2016
  • Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Depression - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Depression - Pipeline by Angelini Group, H2 2016
  • Depression - Pipeline by Angita B.V., H2 2016
  • Depression - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by AstraZeneca Plc, H2 2016
  • Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Axsome Therapeutics Inc, H2 2016
  • Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by BioCrea GmbH, H2 2016
  • Depression - Pipeline by Biogen Inc, H2 2016
  • Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
  • Depression - Pipeline by BioLite, Inc., H2 2016
  • Depression - Pipeline by Bionomics Limited, H2 2016
  • Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Depression - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Depression - Pipeline by Calico LLC, H2 2016
  • Depression - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Depression - Pipeline by Cerecor Inc., H2 2016
  • Depression - Pipeline by Clera Inc., H2 2016
  • Depression - Pipeline by D-Pharm Ltd., H2 2016
  • Depression - Pipeline by Delpor, Inc., H2 2016
  • Depression - Pipeline by e-Therapeutics Plc, H2 2016
  • Depression - Pipeline by Eisai Co., Ltd., H2 2016
  • Depression - Pipeline by Eli Lilly and Company, H2 2016
  • Depression - Pipeline by Evotec AG, H2 2016
  • Depression - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Depression - Pipeline by GliaCure Inc., H2 2016
  • Depression - Pipeline by H. Lundbeck A/S, H2 2016
  • Depression - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Depression - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Depression - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Depression - Pipeline by Impel NeuroPharma, Inc., H2 2016
  • Depression - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Depression - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Depression - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Johnson & Johnson, H2 2016
  • Depression - Pipeline by KemPharm, Inc., H2 2016
  • Depression - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Depression - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Depression - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
  • Depression - Pipeline by Luye Pharma Group Ltd., H2 2016
  • Depression - Pipeline by Mapi Pharma Ltd., H2 2016
  • Depression - Pipeline by Mapreg S.A.S., H2 2016
  • Depression - Pipeline by Meta-IQ ApS, H2 2016
  • Depression - Pipeline by Methylation Sciences Inc., H2 2016
  • Depression - Pipeline by miCure Therapeutics Ltd., H2 2016
  • Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Depression - Pipeline by Navya Biologicals Pvt Ltd, H2 2016
  • Depression - Pipeline by Neuralstem, Inc., H2 2016
  • Depression - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Depression - Pipeline by NeuroNascent, Inc., H2 2016
  • Depression - Pipeline by NeurOp, Inc, H2 2016
  • Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
  • Depression - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
  • Depression - Pipeline by nLife Therapeutics, S.L., H2 2016
  • Depression - Pipeline by Novartis AG, H2 2016
  • Depression - Pipeline by Omeros Corporation, H2 2016
  • Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Depression - Pipeline by Pfizer Inc., H2 2016
  • Depression - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Polleo Pharma Limited, H2 2016
  • Depression - Pipeline by Protagenic Therapeutics Inc., H2 2016
  • Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Depression - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Depression - Pipeline by Saniona AB, H2 2016
  • Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016
  • Depression - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Depression - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Depression - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Depression - Pipeline by Trevena, Inc., H2 2016
  • Depression - Pipeline by TRImaran Pharma, Inc., H2 2016
  • Depression - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2016
  • Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2016
  • Depression - Pipeline by Zogenix, Inc., H2 2016
  • Depression - Pipeline by Zysis Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Depression - Dormant Projects, H2 2016
  • Depression - Dormant Projects (Contd..1), H2 2016
  • Depression - Dormant Projects (Contd..2), H2 2016
  • Depression - Dormant Projects (Contd..3), H2 2016
  • Depression - Dormant Projects (Contd..4), H2 2016
  • Depression - Dormant Projects (Contd..5), H2 2016
  • Depression - Dormant Projects (Contd..6), H2 2016
  • Depression - Dormant Projects (Contd..7), H2 2016
  • Depression - Dormant Projects (Contd..8), H2 2016
  • Depression - Dormant Projects (Contd..9), H2 2016
  • Depression - Dormant Projects (Contd..10), H2 2016
  • Depression - Dormant Projects (Contd..11), H2 2016
  • Depression - Dormant Projects (Contd..12), H2 2016
  • Depression - Dormant Projects (Contd..13), H2 2016
  • Depression - Dormant Projects (Contd..14), H2 2016
  • Depression - Dormant Projects (Contd..15), H2 2016
  • Depression - Dormant Projects (Contd..16), H2 2016
  • Depression - Dormant Projects (Contd..17), H2 2016
  • Depression - Dormant Projects (Contd..18), H2 2016
  • Depression - Dormant Projects (Contd..19), H2 2016
  • Depression - Dormant Projects (Contd..20), H2 2016
  • Depression - Dormant Projects (Contd..21), H2 2016
  • Depression - Dormant Projects (Contd..22), H2 2016
  • Depression - Dormant Projects (Contd..23), H2 2016
  • Depression - Dormant Projects (Contd..24), H2 2016
  • Depression - Discontinued Products, H2 2016
  • Depression - Discontinued Products (Contd..1), H2 2016
  • Depression - Discontinued Products (Contd..2), H2 2016
  • Depression - Discontinued Products (Contd..3), H2 2016
  • Depression - Discontinued Products (Contd..4), H2 2016
  • Depression - Discontinued Products (Contd..5), H2 2016
  • Depression - Discontinued Products (Contd..6), H2 2016
  • Depression - Discontinued Products (Contd..7), H2 2016

List of Figures

  • Number of Products under Development for Depression, H2 2016
  • Number of Products under Development for Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top